NCT03398291

Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a multi-center phase 3 trial to evaluate a treatment strategy for selecting patients who can benefit from the synchronous resection of primary pancreatic cancer and liver oligometastasis after induction chemotherapy. Half of participants who meet the entry criterion will receive surgical intervention, while the other half will continue to receive standard chemotherapy.

Conditions

• Pancreatic Cancer
• Liver Metastases
• Surgery

Interventions

Type	Name	Description
PROCEDURE	Synchronous resection of primary pancreatic cancer and liver oligometastasis	Patients undergo surgical exploration. If no extensive metastatic sites are found, the synchronous resection of primary pancreatic cancer and liver metastatic sites will be performed. Adjuvant chemotherapy was recommended, and the regimen selection is recommended to be based on the preoperative chemotherapy.
DRUG	Standard chemotherapy	Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or gemcitabine plus S-1

Timeline

• Start date: 2018-07-01
• Primary completion: 2023-06-01
• Completion: 2025-06-01
• First posted: 2018-01-12
• Last updated: 2018-10-09

Locations

1 site across 1 country: China